OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.25
+7.14%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.17
From 52W high−57.31%
Volume501401.00
Market cap$91.12M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.17
From 52W high
−57.31%
Volume
501401.00
Market cap
$91.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.5x
P/E (TTM)
—
RSI (14)
22.8
MomentumView details →
1D Return
+7.14%
YTD Return
−27.93%
SummaryUpdated Jun 1, 2026
OnKure Therapeutics, Inc. (NASDAQ:OKUR) is a clinical-stage biotechnology company founded in 2011 and headquartered in Boulder, Colorado. The company specializes in discovering and developing precision oncology medicines, with a particular focus on creating selective inhibitors of histone deacetylases (HDACs) for treating various forms of cancer. OnKure went public through a merger transaction and currently trades on NASDAQ, representing one of the smaller players in the competitive oncology drug development space.
Similar companies
Latest newsMore news →
OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.68d agoOnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.138d ago